Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 27 minutes]
Episode 125 of the NeurologyLive®
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
In this episode, "Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis," Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the new McDonald criteria to diagnose multiple sclerosis (MS), which was presented at the
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Potential Regulatory Submission for Inebilizumab in Myasthenia Gravis Following Positive Phase 3 MINT Data Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor
EPISODE BREAKDOWN
- 1:10 – Focus and direction of new diagnostic criteria
- 3:00 – Overviewing specific changes to McDonald criteria
- 10:50 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier
- 12:55 – Neurology News Minute
- 15:10 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT
- 21:45 – Unanswered questions/challenges left out of the diagnostic criteria
Hoping to listen on your favorite podcast app? See below:
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.